title: [Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
abstract: The WHO 14-days' test and an in vitro survey were carried out to study the efficacy of amodiaquine versus chloroquine in Abie, a hyperendemic village in the southern forest area of Côte-d'Ivoire. One hundred and nineteen children less than 15 years old suffering from uncomplicated malaria were randomised. Among these, 62 were given amodiaquine treatment and 57 chloroquine treatment. both 4-aminoquinoleines were administered at the same dose of 30 mg/kg spread over three days by 10 mg/kg/day. Before the drug was administered, parasites were taken from some patients of each group and were evaluated in vitro to both drugs. In vivo, the amodiaquine treatment shows 95% of clinical success, 2% of early clinical failures and 3% of late clinical failures. For the chloroquine treatment, the rates are respectively. 79%, 7% and 14%. However, some patients still had a level of parasitaemia for both treatments but were asymptomatic. These parasites were found to be resistant in vitro. The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia.
authors.affiliation: Laboratoire de parasitologie-mycologie de l'Institut Pasteur de Côte-d'Ivoire, 01 BP 490 Abidjan 01, RCI. cadjetey@yahoo.fr
authors.forename: T A K
authors.initials: TA
authors.lastname: Adjetey
authors.forename: G B
authors.initials: GB
authors.lastname: Affoumou
authors.forename: D D A
authors.initials: DD
authors.lastname: Loukou
authors.forename: N G F
authors.initials: NG
authors.lastname: Nebavi
authors.forename: P
authors.initials: P
authors.lastname: Barro-Kiki
authors.forename: E I H
authors.initials: EI
authors.lastname: Menan
authors.forename: W
authors.initials: W
authors.lastname: Yavo
authors.forename: M
authors.initials: M
authors.lastname: Kone
mesh_terms: D000655:Amodiaquine / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use*; D007560:Cote d'Ivoire; D004338:Drug Combinations; D018432:Drug Resistance, Multiple; D019353:Endemic Diseases; D005260:Female; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D018512:Parasitemia / Q000188:drug therapy; D010963:Plasmodium falciparum / Q000187:drug effects; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use; D013413:Sulfadoxine / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; D000655:Amodiaquine; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine